Latest Conference Articles
Combination Regimen’s Timing Studied for Patients With CLL/SLL
June 15th 2021, 1:30pm
The study examining venetoclax and obinutuzumab is in progress and currently recruiting patients who are newly diagnosed with asymptomatic, high-risk CLL.
New Results From Capmatinib Study Show Promise for Patient Outcomes
June 9th 2021, 8:23pm
Data were presented at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Conference.
Acalabrutinib Demonstrated Fewer Incidences of Atrial Fibrillation Versus Ibrutinib in Previously Treated Patients With Chronic Lymphocytic Leukemia
June 9th 2021, 6:58pm
Data from a phase 3 trial comparing acalabrutinib against ibrutinib in adults with previously treated CLL showed acalabrutinib presented with non-inferior PFS and significantly fewer events of atrial fibrillation.
Survival Benefits, Established Safety Profile of Single-agent Ibrutinib for CLL Reinforced in Long-term Phase 3 Study
June 9th 2021, 4:58pm
Phase 3 data presented at the 2021 ASCO Annual Meeting have reinforced the long-term survival benefits and well-established safety profile of single-agent ibrutinib for patients with CLL.
Study Data Shows Nivolumab Improves Overall Survival in Unresectable Advanced, Metastatic Esophageal Squamous Cell Carcinoma
June 9th 2021, 12:28pm
Nivolumab and ipilimumab is the first dual immunotherapy combination to demonstrate a superior survival benefit compared to chemotherapy in this setting.
Treatment Developments in Castration-Resistant Metastatic Prostate Cancer
June 9th 2021, 12:16pm
Patients with prostate cancer have to be approached differently depending on the state of their metastases.
New Data Demonstrate Significant Improvement in Hematologic Complete Response with Combination Therapy in Certain Patients With Light Chain Amyloidosis
June 8th 2021, 3:31pm
Analysis from the phase 3 ANDROMEDA study also shows doubling rates of organ response with no new safety signals for patients taking daratumumab and hyaluronidase-fihj.
Developing CAR T-Cell Therapies Offer Treatment Opportunities for Mantle Cell Lymphoma
June 8th 2021, 3:04pm
Although historic study results with mantel cell lymphoma showed discouraging findings, new CAR T-cell therapies routinely show between 40% and 50% of patients respond long-term without relapsing.
Novel Targeted Therapies Present Opportunities in Multiple Cancer Types
June 8th 2021, 2:55pm
Investigative and newly approved drugs targeting RET activity and KRAS-related mutations are showing deep, durable responses in several types of cancers.
Choosing the Right Checkpoint Inhibitor Combination Therapy for First-Line Advanced Non–Small Cell Lung Cancer
June 8th 2021, 2:40pm
While discussing a few case studies, the panel was able to make appropriate treatment decisions for each patient and emphasized the importance of communicating with patients as a physician.